Business, energy, technology, markets and global industry news from Business News Today

sacituzumab govitecan-hziy

PharmaDeviceNews sacituzumab govitecan-hziy
Pharma & Biotech

Merck and Gilead secure FDA approval for a new ADC-immunotherapy backbone in advanced TNBC

The new regimen replaces conventional chemotherapy with a Trop-2-directed antibody-drug conjugate while retaining PD-1 blockade, offering longer disease control but leaving overall survival, sequencing and cost questions unresolved.

Read More
Representative image: Trodelvy’s first-line FDA approval could reshape metastatic triple-negative breast cancer treatment by expanding options across PD-L1 patient groups.
Pharma & Biotech

Gilead expands Trodelvy into first-line metastatic TNBC, but survival questions remain unresolved

The decision gives clinicians a Trodelvy-based option for patients who cannot receive checkpoint inhibitors and a Trodelvy plus Keytruda regimen for PD-L1-positive disease. The immediate clinical impact is substantial, although immature overall-survival data, toxicity management and treatment cost will influence how rapidly the new pathways displace chemotherapy.

Read More